Influence of the polymorphisms of genes Mu 1 (GSTM1), Theta 1 (GSTT1), XPD Asp312Asn e XPD Lys751Gln in cutaneous melanoma susceptibility

Orientador: Carmen Silvia Passos LimaTese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências MédicasResumo: As glutationa S-transferases (GSTs) são enzimas detoxificantes. Os genes GSTM1 e GSTT1 são polimórficos e quando deletados perdem a expressão enzimática. As proteínas codificadas pelos genes XPD são responsáveis pelo reparo de lesões do DNA causadas pela luz solar. Polimorfismos nestes genes também podem codificar proteínas com funções comprometidas, em especial o Lys751Gln e o Asp312Asn do gene XPD. Ainda não é claro o papel dos polimorfismos destes genes no risco de melanoma cutâneo (MC) ou se estão associados com os aspectos clínicopatológicos. Foram incluídos 489 indivíduos (231 pacientes, 258 controles). A genotipagem foi realizada por reação em cadeia da polimerase e digestão enzimática. O risco de MC esteve aumentado em 2,00 (IC 95%: 1,05-3,81, P= 0,03) vezes em portadores do genótipo GSTT1 nulo + Asp/Asn + Asn/Asn do XPD Asp312Asn. O GSTT1 nulo elevou o risco de MC metastático em 3,75 (IC 95%: 1,48-9,44, P= 0,006) vezes e se combinado ao GSTM1 nulo em 7,33 (IC 95%: 2,09-25,68, P= 0,003) vezes. O alelo 312Asn elevou o risco de MC no tronco ou membros em 1,80 (IC 95%: 1,19-2,73, P= 0,005) vezes e do subtipo extensivo superficial ou nodular em 1,80 (IC 95%: 1,14-2,84, P= 0,01) vezes. Os genótipos Asn/Asn + Gln/Gln elevou o risco de MC de níveis I, II ou III de Clark em 2,46 (IC 95%: 1,12-5,37, P= 0,02) vezes. Os genótipos GSTM1 nulo + GSTT1 nulo (HR: 3,18; IC95%: 1,21-8,36, P= 0,01) e o genótipo GSTT1nulo + Gln/Gln (HR: 5,93; IC95%: 1,53-22,91, P= 0,01) estiveram associados a maior risco de morte. Concluímos que os referidos polimorfismos em combinações específicas podem aumentar a susceptibilidade ao MC e influenciar suas características clínicopatológicas e sobrevidaAbstract: The glutathione S-transferases (GST) are detoxifying enzymes; the GSTM1 and GSTT1 genes are polymorphic and when deleted lose enzyme expression. The XPD proteins are responsible for DNA damage repair caused by sunlight. Polymorphisms (SNPs) in XPD genes may also result proteins with impaired function, in particular Lys751Gln and Asp312Asn. However It¿s not entirely clear whether the SNPs of these genes influence the risk of cutaneous melanoma (CM) or are associated with clinic pathological aspects of this disease. In the present study 489 individuals were included (231 patients and 258 controls). Genotyping was performed by polymerase chain reaction and enzyme digestion. The risk of MC was increased 2.00-fold (95% CI: 1.05-3.81, P= 0.03) in carriers of the GSTT1 null combined with Asp/Asn + Asn/Asn genotype of XPD Asp312Asn. The GSTT1 null genotype and GSTT1 null + GSTM1 null genotype increased the risk of metastatic MC by 3.75-fold (95% CI: 1.48-9.44, P= 0.006) and 7.33-fold (95% CI: 2.09-25.68, P= 0.003), respectively. The allele 312Asn increased the risk of MC in the trunk or limbs in 1.80-fold (95% CI: 1.19-2.73, P= 0.005) and superficial spreading or nodular subtype in 1.80-fold (95%: 1.14-2.84, P= 0.01). The combined Asn/Asn + Gln/Gln genotype raised the risk of MC in Clark¿s level I, II or III in 2.46-fold (95% CI: 1.12-5.37, P= 0.02). The genotype GSTM1null + GSTT1 null (HR: 3.18; 95% CI: 1.21-8.36, P= 0.01) and GSTT1 null + Gln/Gln (HR: 5.93; 95% CI: 1.53-22.91, P= 0.01) were predictive of lower overall survival. In conclusion, polymorphisms in specific genes combinations may increase susceptibility to MC and influence their clinic pathological features and survivalDoutoradoClinica MedicaDoutor em Clínica Médic

Neoadjuvant Endocrine Therapy For Resectable Breast Cancer: A Systematic Review And Meta-analysis.

The role of neoadjuvant endocrine therapy for resectable breast cancer is not well established, despite encouraging results obtained in the metastatic and adjuvant settings. This systematic review aims to examine existing medical literature on neoadjuvant hormone therapy (HT). Data from prospective, randomized trials was included if comparing neoadjuvant HT versus surgery alone without adjuvant treatment, or neoadjuvant HT versus chemotherapy (CT), or HT plus CT versus CT alone, or HT plus CT versus HT alone, or two distinct HT. Odds Ratios (OR) were calculated from pooled data. Five studies compared HT with tamoxifen versus HT with aromatase inhibitors (AI). A meta-analysis of their results demonstrated superiority of AIs in overall response rate (ORR) (OR 1.9; 95% CI 1.17-3.08). Two trials compared HT against CT, and pooled data from them demonstrated a trend favoring CT (OR for ORR 0.75; 95% CI 0.35-1.6). That trend disappeared when only postmenopausal women were considered (OR 1.01; 95% CI 0.62-1.63). One trial compared HT plus CT with no neoadjuvant treatment, and obtained an 83% ORR. One trial compared HT plus CT versus CT alone and found a non-significant increase in ORR for adding HT to CT (OR 1.48; 95% CI 0.58-3.77). No trial compared HT plus CT versus HT alone. Neoadjuvant HT is a safe and feasible option, but it cannot be considered equivalent to CT. If neoadjuvant HT is performed, AIs are preferable over tamoxifen due to higher response rates.24406-41

Xpc (a2920c), Xpf (t30028c), Tp53 (arg72pro), And Gstp1 (ile105val) Polymorphisms In Prognosis Of Cutaneous Melanoma.

This study aimed to evaluate whether XPC A2920C, XPF T30028C, TP53 Arg72Pro, and GSTP1 Ile105Val polymorphisms alter outcomes of cutaneous melanoma (CM) patients. DNA from 237 CM patients seen at the University of Campinas Teaching Hospital from April 2000 to February 2014 was analyzed by polymerase chain reaction and restriction fragment length polymorphism assays. The prognostic impact of genotypes of polymorphisms on progression-free survival (PFS) and overall survival (OS) of CM patients were examined using the Kaplan-Meier probability estimates and univariate and multivariate Cox regression analyses. At 60 months of follow-up, shorter PFS and OS were seen in patients with XPF CC genotype (48.9 vs. 66.7 %, P = 0.002; 77.9 vs. 83.5 %, P = 0.006, respectively) and XPF CC + TP53 ArgArg (43.6 vs. 65.9 %, P = 0.007; 71.6 vs. 84.8 %, P = 0.006, respectively) compared with those with remaining genotypes (Kaplan-Meier estimates). Patients with XPF CC (hazard ratio (HR) 2.45, P = 0.002; HR 3.77, P = 0.005) and XPF CC + TP53 ArgArg (HR 2.67, P = 0.009; HR 4.04, P = 0.03) genotypes had more chance to present tumor progression in univariate and multivariate analyses, whereas patients with XPF CC (HR 2.78, P = 0.009) and XPF CC + TP53 ArgArg (HR 3.84, P = 0.01) genotypes were under greater risk of progressing to death in univariate analysis, compared with those with the remaining genotypes. The data suggest, for the first time, that inherited abnormalities in DNA repair pathway related to XPF 30028C and TP53 Arg72Pro polymorphisms act as prognostic factors for PFS and OS of CM patients

MLH1, MSH2, MSH3 and EXO1 polymorphisms and head and neck squamous cell carcinoma risk and prognosis

Sem informação3315Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cance